DEVARTLab, a pioneer company
in the manufacture of functional foods, nutritional supplements, and
therapeutic drugs, organized its 43rd conference, under title "For Better
Health and maximum Protection from Cardiovascular Diseases" in presence of elite
professors of cardiology, and internal medicine from various universities in
Egypt to improve the level of public health
The conference discussed many topics related to atherosclerosis,
identifying integrated methods of treatment, reducing blood lipids and arteries
calcification through effective products, "Advochol" and "Mena Q"
in a lecture by Prof. Dr. Ahmed Abdel Rahman, Professor of Cardiology, Ain
Shams University, in addition to discussing everything new in high blood
pressure management and the use of new and effective formulations in this field
using Nepvol and Amlo - ACE in a lecture by Prof. Dr. Maged Ramses, Professor
of Cardiology and Head of Cardiology Department at National Heart Institute
The conference also discussed iron deficiency anemia management by using
products with new technology guarantees maximum effectiveness without any side
effects, “Pharafero 18 and Pharafero 18 Plus”, in a lecture by Prof. Dr.
Bassem Zarif, Professor of Cardiology and Vice Dean of National Heart Institute
Where Dr. Bassem Zarif, addressed at the conference everything
related to iron deficiency anemia management indicating that there is a
national tendency for iron deficiency anemia eradication, explaining that the
new technology of DEVARTLab products, has distinct properties that
significantly improve the absorption of iron and does not cause any side
effects such as indigestion, stomach pain, and complications, stressing that "DEVARTLab"
company has made a breakthrough in iron deficiency anemia management in Egypt.
Pointing out that anemia has a negative effect on heart failure patient
recovery
Dr. Ahmed Abdel Rahman, added that the conference discussed the mechanism
of protecting patients with atherosclerosis,
And the role of "Advochol" to reduce blood lipids level, in
addition to the role of "Mena Q" to prevent calcium deposition and to
protect patients’ arteries